<DOC>
	<DOCNO>NCT00158288</DOCNO>
	<brief_summary>Although LAAM , derivative methadone , successfully use alternative methadone maintenance opioid addict , effect concurrent opioid cocaine abuse ascertain . Thus , study proposes examine clinical efficacy low- high-dose LAAM maintenance opioid cocaine use opioid-dependent cocaine abuser . In addition , since contingency management procedure demonstrate success decrease cocaine use cocaine-abusing individual , study also propose examine clinical efficacy presence absence contingency management procedure target illicit drug use .</brief_summary>
	<brief_title>The Efficacy Methadyl Acetate ( LAAM ) Contingency Management Procedures Treating Dual Opioid Cocaine Abuse - 1</brief_title>
	<detailed_description>One hundred forty male female opioid-dependent cocaine abuser stratify sex randomly assign one four treatment group accord 2 x 2 experimental design : low-dose LAAM ( 99 mg/wk ) adjunct contingency management procedure ; low-dose LAAM ( 99 mg/wk ) without adjunct contingency management procedure ; high-dose LAAM ( 330 mg/wk ) adjunct contingency management procedure ; high-dose LAAM ( 330 mg/wk ) without adjunct contingency management procedure . The duration study 24 week , LAAM administer thrice-weekly ( MWF ) basis . Subjects induct onto LAAM week 1-3 maintain assigned maintenance dose ( 99 mg/wk 330 mg/wk ) week 24 . During maintenance , Friday dose 1.3 time great Monday Wednesday dose . At conclusion study , subject undergo detoxification LAAM 4-week period . For contingency management procedure group , drug-free urine submit result voucher worth certain monetary value increase consecutively drug-free urine ( week 1-12 ) monetary voucher fix value ( week 13-24 ) . Subjects assign contingency management procedure receive monetary voucher ( week 1-24 ) accord yoked-control schedule ( , contingent upon illicit drug abstinence ) . Vouchers exchange mutually agree upon good service time study . Outcome measure include : 1 ) treatment retention , 2 ) illicit drug use , 3 ) self-reported adverse opioid withdrawal symptom , 4 ) psychosocial function . Follow-up interview nine month and/or one year post-study entry conduct determine status post-treatment . Prognostic factor ( i.e. , sex , post-traumatic stress disorder , depression ) , also examine relation treatment outcome post-treatment status .</detailed_description>
	<mesh_term>Substance-Related Disorders</mesh_term>
	<mesh_term>Cocaine-Related Disorders</mesh_term>
	<mesh_term>Heroin Dependence</mesh_term>
	<mesh_term>Cocaine</mesh_term>
	<criteria>One hundred forty male female cocaineabusing , opioiddependent individual age 2155 , least 40 % woman 40 % AfroAmericans , currently enrol treatment , enter study . Subjects must current opioid dependence evidence documentation prior treatment opioid dependence sign withdrawal upon administration naloxone ( 0.8 mg , i.m . ) , opioidpositive urine screen . Subjects also must current user cocaine selfreported use &gt; 12 gm precede 12 month , selfreported use &gt; 1 gm/week month precede study entry , cocainepositive urine screen . Subjects must fulfill DSMIIIR criterion opioid cocaine dependence . These criterion ascertain use substance abuse section SCID interview develop use DSMIIIR Criteria exclusion include current diagnosis drug alcohol dependence ( opiate , cocaine tobacco ) ; ill health ( e.g. , major cardiovascular , renal , endocrine , hepatic disorder ) ; respiratory condition ( e.g. , asthma ) ; history major psychiatric disorder ( psychosis , schizophrenia , bipolar , major depression ) ; current suicidality ; LFT 's ( i.e. , liver enzymes ) great 3 time normal level ; pregnancy .</criteria>
	<gender>All</gender>
	<minimum_age>21 Years</minimum_age>
	<maximum_age>55 Years</maximum_age>
	<verification_date>September 2005</verification_date>
	<keyword>Substance Use Disorders</keyword>
</DOC>